T-Cell LymphomaSymptoms, Doctors, Treatments, Advances & More
Learn About T-Cell Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
CUIMC/Herbert Irving Pavilion
Larisa Geskin is an Oncologist in New York, New York. Dr. Geskin is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Sezary Syndrome.
Christiane Querfeld, M.D., PH.D.
Christiane Querfeld is a Dermatologist in Duarte, California. Dr. Querfeld is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.
WPHPA Cancer And Blood Specialists Of New York
Dr. Owen A. O'Connor is internationally renowned for his expertise on the diagnosis and treatment of all forms of lymphoma, with over 25 years of experience in academic medicine. He has invented and pioneered the development of several first in class drugs for the treatment of lymphoma, including one he co-invented for T-cell lymphoma which has now been approved in over 35 countries around the world. He has held several prestigious leadership positions at the major cancer centers in New York City, including Memorial Sloan Kettering Cancer Center, New York University Medical Center, and Cornell and Columbia University Medical Centers. Dr. O'connor is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Anaplastic Large Cell Lymphoma.
Summary: The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.
Summary: This study is a platform trial for the evaluation of new drugs or combination of drugs in relapsed or refractory peripheral T-cell lymphomas. The objective of the study is to generate exploratory data on new drugs or combination of drugs to treat refractory/relapse peripheral T-cells lymphoma to better identify the population of interest and design future correct clinical trials. Primary objective...